

treated at -3 days and -1 pre-surgery, followed by post-surgery weekly boosting. HLI was achieved by unilateral ligation and excision of the femoral artery of the left hind limb. The right hind limb served as non-ischemic control. Gene expression analysis in the hind limbs 3 days post HLI showed decreased miR29a expression in normal chow fed B6, but elevated miR29a expression in HFD (B6 vs HFD;  $0.5730 \pm 0.01$  vs  $1.02 \pm 0.06$ ,  $n=3-4$ ,  $p=0.001$ ). Treatment with miR29a inhibitor decreased miR29a expression in HFD and increased ADAM12 expression compared to control untreated HFD mice (miR29a INH vs Control HFD:  $0.70 \pm 0.06$  vs  $1.02 \pm 0.06$ ,  $n=4-5$ ,  $p=0.004$ ) ADAM12 expression (miR29a INH vs Control: HFD  $208.62 \pm 24.52$  vs  $11.75 \pm 4.94$ ,  $n=3-4$ ,  $p<0.01$ ). Although ADAM12 cDNA improved ADAM12 expression, miR29a inhibition increased ADAM12 expression to a greater extent (HFD vs ADAM12 vs miR29aINH;  $11.75 \pm 4.94$  vs  $20.71 \pm 2.98$  vs  $208.62 \pm 24.52$ ,  $n=3-4$ ,  $p<0.001$ ). Accordingly, miR29a inhibition and ADAM12 augmentation decreased skeletal muscle injury assessed by the number of centralized nuclei/muscle fibre (Control vs ADAM12 vs miR29aINH:  $0.252 \pm 0.043$ , vs  $0.139 \pm 0.041$  vs  $0.040 \pm 0.012$ ,  $n=4$ ,  $p=0.05$ ), and improved skeletal muscle function assessed as maximum muscle contraction (Control vs ADAM12 vs miR29aINH:  $0.17 \pm 0.06$  vs  $0.26 \pm 0.06$ , vs  $0.54 \pm 0.08$ ,  $n=6-7$ ,  $p<0.01$ ). It also improved perfusion recovery, (% ischemic to non-ischemic limb, control vs ADAM12 vs miR29aINH:  $42.52 \pm 5.35$ , vs  $58.45 \pm 4.87$ , vs  $97.59 \pm 6.14$ ,  $n=5-10$ ,  $p<0.01$ ). Thus, our results show augmentation of ADAM12 and Inhibition of MiR29a improves outcomes in experimental PAD in diabetic mice but inhibiting miR29a is a more effective strategy.

## Cardiovascular Endocrinology

### CARDIOVASCULAR ENDOCRINOLOGY

#### *Insulin Resistance Is Associated With Impaired HDL Function and Atherogenic Modification of LDL in Polycystic Ovarian Syndrome*

Jan Hoong Ho, MBChB, MRCP<sup>1</sup>, Safwaan Adam, MBChB MRCP<sup>2</sup>, Yifen Liu, Dr, PhD<sup>1</sup>, Shaishav Dhage, DNB MRCP MRCP ENDOCRINOLOGY<sup>3</sup>, Sotirios Tsimikas, MD<sup>4</sup>, Handrean Soran, MD<sup>1</sup>, James Gibney, MD<sup>5</sup>.

<sup>1</sup>University of Manchester, Manchester, United Kingdom,

<sup>2</sup>THE CHRISTIE NHS FOUNDATION TRUST, Bolton, United Kingdom, <sup>3</sup>North West Deanery, Bolton, United Kingdom,

<sup>4</sup>University of California San Diego, San Diego, CA, USA,

<sup>5</sup>Tallaght University Hospital, Dublin, Ireland.

**Background and Aims:** Polycystic ovarian syndrome (PCOS) is associated with increased risk of cardiovascular disease (CVD). The aim of this study was to assess the association between PCOS and markers of HDL functionality and atherogenic LDL modification. **Methods:** This is a cross-sectional study of 104 women with PCOS [median (IQR); age 29 (24–36) years, and BMI  $32.9$  ( $25.7-38.5$ )  $\text{kg/m}^2$ ] and 103 BMI-matched healthy participants (age 34 (27–37) years, and BMI  $31.1$  ( $27.6-35.5$ )  $\text{kg/m}^2$ ). PCOS was defined using the NIH criteria. Measurement of lipid profile and glycaemic blood parameters were undertaken. Patients with PCOS were divided into tertiles of insulin resistance assessed using the homeostatic model

assessment (HOMA-IR). Cholesterol efflux capacity (CEC), and paraoxonase-1 (PON1) activity were measured as markers of HDL functionality. Oxidized LDL (OxLDL), lipoprotein-associated phospholipase A2 (LpPLA2), oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) and apolipoprotein(a) (OxPL-apo(a)), and glycated apoB were used as markers of atherogenic modification of LDL. **Results:** Patients with PCOS in the upper tertile of insulin resistance had impaired HDL functionality compared to the lower tertile and controls, with lower CEC [ $13.7$  ( $12.4-14.6$ ) vs  $14.9$  ( $13.6-17.0$ ),  $P=0.003$ ; and  $14.5$  ( $13.0-16.0$ ) %,  $P=0.063$  respectively] and PON1 activity [ $77.2$  ( $48.2-129.2$ ) vs  $112.9$  ( $54.0-175.4$ ),  $P=0.043$ ; and  $131.6$  ( $89.5-195.1$ ) nmol/ml/min,  $P<0.001$  respectively]. Markers of atherogenic modification of LDL were also increased in the upper tertile compared to the lower tertile and controls, with higher levels of OxLDL [ $91.6$  ( $58.8-120.9$ ) vs  $67.2$  ( $20.1-86.3$ ),  $P=0.016$ ; and  $74.8$  ( $47.6-89.5$ ) ng/ml,  $P=0.013$  respectively], LpPLA2 [ $1.66$  ( $1.48-1.84$ ) vs  $1.48$  ( $1.39-1.60$ ),  $P=0.004$ ; and  $1.53$  ( $1.37-1.70$ )  $\mu\text{g/ml}$ ,  $P=0.015$  respectively], small-dense LDL cholesterol (sdLDL) [ $24.8$  ( $16.8-35.0$ ) vs  $15.3$  ( $11.3-20.1$ ),  $P<0.001$ ; and  $20.9$  ( $14.6-29.0$ ) mg/dl,  $P<0.001$  respectively], and glycated apoB [ $4.02$  ( $3.63-4.33$ ) vs  $3.51$  ( $3.27-3.70$ ),  $P<0.001$ ; and  $3.48$  ( $3.20-3.96$ ),  $P<0.001$  respectively]. Both BMI and insulin resistance were associated with adverse lipoprotein modification, correlating positively with OxLDL, LpPLA2, sdLDL, and glycated apoB (Spearman's  $\rho=0.244-0.325$  and Spearman's  $\rho=0.254-0.377$  respectively, all  $P<0.050$ ); and negatively with CEC (Spearman's  $\rho=-0.244$  and Spearman's  $\rho=0.254$  respectively, both  $P<0.050$ ). OxPL-apoB, OxPL-apo(a), and lipoprotein(a) did not differ between PCOS and controls. **Conclusions:** Insulin resistance is a key determinant of decreased HDL functionality and increased oxidative modification and glycation of LDL in PCOS, which is likely to contribute to the increased CVD risk.

## Cardiovascular Endocrinology

### CARDIOVASCULAR ENDOCRINOLOGY

#### *Interaction Between Wnt $\beta$ -catenin and ACTH Signaling Pathways and Paracrine Regulation in Aldosterone Producing Adenoma*

Alaa B. Abdellatif, MSc<sup>1</sup>, Kelly De Sousa, PhD<sup>1</sup>, Isabelle Giscos-Douriez, Ms<sup>1</sup>, Tchao Meatchi, MD<sup>2</sup>, Laurence Amar, MD, PhD<sup>3</sup>, Fabio L. Fernandes Rosa, MD, PhD<sup>1</sup>, Sheerazed Boulkroun, PhD<sup>1</sup>, Maria-Christina Zennaro, MD, PhD<sup>1</sup>.

<sup>1</sup>Université de Paris, PARCC, INSERM, Paris, France,

<sup>2</sup>Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d'Anatomie Pathologique, Paris, France,

<sup>3</sup>Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Unité Hypertension artérielle, Paris, France.

Primary aldosteronism (PA) is the most frequent form of secondary arterial hypertension and is caused in the majority of cases by an aldosterone producing adenoma (APA) or bilateral adrenal hyperplasia. Different somatic mutations have been identified in APA and in other aldosterone producing structures, which can be distinct within the same adrenal, suggesting multiple mechanisms underlying

APA development. Also, APA show important cellular and molecular heterogeneity which may be due to interaction of different signaling pathways involved in adrenal cortex cell differentiation and function. The aim of this study was to investigate the role of Wnt/ $\beta$ -catenin and ACTH signaling as well as elements of paracrine regulation of aldosterone biosynthesis and vascularization in the development of APA and aldosterone producing cell clusters (APCC) and their relationship with intratumoral heterogeneity and mutational status. We performed immunohistochemistry and multiplex immunofluorescence (CYP11B2, CYP17A1,  $\beta$ -catenin, MC2R, pCREB, Tryptase, S100, CD34) multi-spectral image analysis on 11 adrenals with APA and one with micronodular hyperplasia from patients with PA. CYP11B2 (aldosterone synthase) IHC guided RT-qPCR was performed on RNA extracted from formalin-fixed paraffin-embedded tissues in 7 adrenals. Multiplex immunofluorescence revealed high abundance of tryptase positive mast cells and a dense vascular component in APA, which were independent of the mutational status. Within APA, mast cells were mainly localized in zones expressing CYP11B2, but not in areas expressing CYP17A1, and were rarely colocalized with nerve fibers, suggesting that their activity is not controlled by innervation. In cells expressing aldosterone synthase,  $\beta$ -catenin was activated, i.e. shows nuclear and/or cytoplasmic staining, features suggestive of a zona glomerulosa cell identity; MC2R was found at the cell membrane. Expression of *MC2R* mRNA was observed at different levels in APA, similar to expression of *MRAP* and *VEGFA*; *MRAP2* was not detected. Within heterogeneous APA carrying *KCNJ5* mutations, both *MC2R* and *VEGFA* expression was higher in areas expressing CYP11B2. Remarkably, this pattern was maintained in APCC, where cells show high CYP11B2 expression, together with activated  $\beta$ -catenin, independently of the mutation status. In addition, a high number of mast cells was detected around APCC, with a reorganization of the capillaries around the CYP11B2 positive cells. Our results suggest that aldosterone producing structures in adrenals with APA share common molecular characteristics and cellular environment, despite different mutation status. Mast cells appear to be closely associated with cells expressing aldosterone synthase, both in APA and APCC, and their role in regulating aldosterone biosynthesis in the context of somatic mutations in PA remains to be established.

## Cardiovascular Endocrinology

### CARDIOVASCULAR ENDOCRINOLOGY

#### *Laterality Diagnosis of Adrenal Vein Sampling for Primary Aldosteronism Using Aldosterone Alone*

Norio Wada, MD, PhD, Shuhei Baba, MD, Hajime Sugawara, MD, Arina Miyoshi, MD, PhD, Shinji Obara, MD, Hiroaki Usubuchi, MD, Satoshi Terae, MD, PhD.  
Sapporo City General Hospital, SAPPORO, Japan.

**Background:** In adrenal vein sampling (AVS) for primary aldosteronism (PA), cortisol concentration is used to determine successful AVS, and laterality diagnosis is performed using a combination of aldosterone and cortisol concentrations. In this study, we examined the comparison with the conventional method when AVS was determined

by aldosterone alone. **Subjects and methods:** We studied the data from 277 patients with PA who underwent AVS in Sapporo City General Hospital from July 2007 to April 2020. The patients with autonomous cortisol production were excluded. Using the blood samples from adrenal veins and inferior vena cava (IVC) after ACTH stimulation, the predicting ability of the left and right ratio of aldosterone concentration (aldosterone ratio, AR) for lateralization Index (LI) was examined by Receiver operating characteristic (ROC) analysis. The predicting abilities of the ratio of aldosterone concentration between adrenal vein and IVC (aldosterone index, AI) and aldosterone concentration for selectivity index (SI) and contralateral ratio (CR) were also examined by ROC analysis. **Results:** Six samples (0.01%) with SI <5 after ACTH stimulation those were determined unsuccessful AVS. The results of the area under the curve (AUC) in ROC analysis of aldosterone concentration and AI for prediction of SI>5 was 0.998, 0.990, respectively,  $p=0.39$ . The optimal cut-off values of aldosterone concentration and AI for prediction successful AVS were 1700 pg/ml (sensitivity 99.5%, specificity 100%), 7.44 (sensitivity 94.0%, specificity 100%), respectively. Seventy-two patients (27.3%) had LI >4 who were diagnosed as unilateral aldosterone excess. AR had 0.94 of AUC for prediction of LR >4. The optimal cut-off value of AR was 3.53 (sensitivity 86.1%, specificity 94.8%). Eighty-two patients (31.1%) had unilateral CR<1. The AUC of aldosterone concentration and AI for prediction of CR<1 was 0.96, 0.98, respectively,  $p=0.07$ . The optimal cut-off values of aldosterone concentration and AI were 13600 pg/ml, 42, respectively. The sensitivity and the specificity at the optimal cut-off points of aldosterone concentration and AI were 91.5%, 91.5% and 91.5%, 94.8%, respectively. **Conclusions:** The determination of successful AVS and unilateral result in AVS can be predicted using aldosterone alone. It was suggested that AR is useful for tentative interpretation in the cases where the results of aldosterone were previously reported and lateralizing diagnosis of the cases with autonomous cortisol production.

## Cardiovascular Endocrinology

### CARDIOVASCULAR ENDOCRINOLOGY

#### *Lipoprotein Insulin Resistance Score: Validation and Utility in African Ancestry Populations*

Vandhna Rani Sharma, MD, Celeste K.L. Cravalho, BS, Joshua Dawson, BS, Alfredo Villalobos-Perez, BA, Lilian Mabundo, BS, Samantha Matta, BS, Christopher DuBose, BS, Anne E. Sumner, MD, Stephanie Therese Chung, MBBS.  
NIDDK-NIH, Bethesda, MD, USA.

Lipoprotein insulin resistance (LPIR) is an emerging biomarker of insulin resistance (IR), and a score of >48 is a strong predictor of incident cardiometabolic disease in a predominantly European ancestry population. LPIR is derived from a composite score of nuclear magnetic resonance (NMR) lipoprotein (Lp) parameters: triglyceride-rich (TRLp), low density (LDLp), and high density (HDLp). Yet, there is a paucity of data in African ancestry population, in whom there is low-normal TRLp despite high rates of IR and diabetes. Therefore, we examined Lp profiles and LPIR in a large African ancestry cohort, stratified by sex to determine the relationship of LPIR with established markers